Evidence map›Paper›PMID 17223855›Full record

Trial reportBritish journal of clinical pharmacology2007

Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide.

Jari J Lilja, Mikko Niemi, Hanna Fredrikson, Pertti J Neuvonen

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in British journal of clinical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Population Pharmacokinetic Modeling Study of Glibenclamide in Chinese Healthy Volunteers.European journal of drug metabolism and pharmacokinetics · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Sucralose, a synthetic organochlorine sweetener: overview of biological issues.Journal of toxicology and environmental health. Part B, Critical reviews · 2013
    Review
  16. Article
  17. Article
  18. The effect of grapefruit juice on drug disposition.Expert opinion on drug metabolism & toxicology · 2011
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jari J LiljaDepartment of Clinical Pharmacology, University of Helsinki, Helsinki, Finland. jari.lilja@hus.fi
Mikko Niemi
Hanna Fredrikson
Pertti J Neuvonen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCase reports suggest that clarithromycin can increase the glucose-lowering effect of glibenclamide which is metabolized mainly by CYP2C9 and is a substrate for P-glycoprotein and OATP2B1. Our objective was to evaluate whether the P-glycoprotein inhibitor, clarithromycin, increases and the putative OATP2B1 inhibitor, grapefruit juice, decreases plasma concentrations of glibenclamide.

methodsIn a randomized three-phase crossover study, 12 subjects ingested 250 mg clarithromycin or placebo twice daily or 200 ml grapefruit juice three times daily for 2 days. On day 3, they ingested 0.875 mg glibenclamide with sugar water or grapefruit juice. Concentrations of glibenclamide and clarithromycin in plasma, glucose in blood, and excretion of hydroxy-glibenclamide into urine were measured up to 12 h.

resultsClarithromycin increased the peak concentration (C(max)) of glibenclamide to 1.25-fold (95% confidence interval (CI) 1.12, 1.40; P < 0.01) and the area under the plasma concentration-time curve to 1.35-fold (95% CI 1.21, 1.50; P < 0.01) compared with the placebo phase. The time to C(max), the half-life of glibenclamide, and the amount of hydroxy-glibenclamide excreted into urine remained unaltered. Grapefruit juice did not change the pharmacokinetics of glibenclamide. Clarithromycin concentrations implied a good compliance. Blood glucose did not deviate between the phases.

conclusionsClarithromycin increased plasma concentrations of glibenclamide, possibly by inhibiting P-glycoprotein in the intestinal wall. Although not seen with the present study design, clarithromycin may enhance the effect of glibenclamide by increasing plasma glibenclamide concentrations, which warrants close monitoring of blood glucose during their co-administration. Grapefruit juice had no effect on glibenclamide pharmacokinetics.

Indexed as

Citrus paradisiDrug InteractionsAdultBeveragesClarithromycinCross-Over StudiesFemaleGlyburideHumansHypoglycemic AgentsMaleProtein Synthesis InhibitorsClarithromycinGlyburideHypoglycemic AgentsProtein Synthesis Inhibitors

Identifiers

PMID17223855
PMCPMC2000598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.